glp 1 for insulin resistance GLP-1-based therapies type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation | Diabetology & Metabolic Syndrome GLP-1 Agonists - What is

Colleen McCabe, PharmD, BCOP, and Lindsay Mundy, PharmD, BCOP, provided an engaging exploration of the benefits and potential pitfalls seen with the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in an oncology setting

Ideal Protein Alternatives (Restricted)

An endocrinologist explains who the pill is right for in the UAE, what the trial numbers actually say, and when the injection still wins.

Covers SURPASS/SURMOUNT trials, dosing, and semaglutide comparison.

Glucagon-like peptide-1 (GLP-1) is a gut-derived hormone essential for maintaining glucose homeostasis through multiple physiological pathways: triggering insulin release, inhibiting glucagon secretion, delaying gastric emptying, enhancing feelings of fullness, and suppressing appetite

Identification of genetic variants associated with the efficacy and side effects of GLP1 medications could underpin development of precision medicine approaches in the treatment of obesity.